Aberdeen Group plc Has $15.83 Million Stock Position in Immunovant, Inc. $IMVT
Aberdeen Group plc significantly increased its stake in Immunovant, Inc. (NASDAQ:IMVT) by 16.2% in the third quarter, bringing its total holdings to 981,804 shares valued at approximately $15.83 million. Immunovant shares opened at $26.65, trading within a 52-week range of $12.72–$27.92, and the company has a market cap of $5.42 billion. Analyst sentiment for IMVT is generally favorable, with a "Moderate Buy" consensus and an average price target of $31.11, despite some recent insider selling.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)
Purcell & Lefkowitz LLP has initiated a shareholder investigation into Immunovant, Inc. (NASDAQ: IMVT). The firm is looking into whether Immunovant's directors breached their fiduciary duties through recent corporate actions. Shareholders of Immunovant are encouraged to contact the law firm for more information regarding their rights and options.
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Moderate Buy" from Analysts
Immunovant, Inc. (NASDAQ:IMVT) has an average "Moderate Buy" rating from analysts, with a consensus 12-month price target of $31.11. The company recently reported Q3 EPS of ($0.61), beating estimates, and analysts project ($2.69) EPS for the current year. Insider selling occurred last quarter, but institutions hold a significant portion of the stock.
Technical Reactions to IMVT Trends in Macro Strategies
This article analyzes Immunovant Inc. (NASDAQ: IMVT) using AI models to provide technical reactions and trading strategies. It highlights a near-term strong sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup. Three distinct trading strategies are offered for different risk profiles, along with multi-timeframe signal analysis.
FY2030 EPS Estimates for Immunovant Raised by HC Wainwright
HC Wainwright has increased its FY2030 EPS estimate for Immunovant (NASDAQ:IMVT) to $2.91 from $2.84, reiterating a "Buy" rating and a $35 price target. Despite this, the consensus current full-year estimate for Immunovant remains a loss of ($2.69) per share. Analyst coverage on the stock is generally positive, with a "Moderate Buy" consensus rating and an average price target of $31.11, while insiders have been net sellers, and hedge funds and institutions hold a significant portion of the stock.
Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected
Immunovant's shares climbed 7% after the company reported better-than-expected fiscal Q3 results. The company's loss per share was narrower than anticipated, contributing to the positive market reaction.
Immunovant (NASDAQ:IMVT) Given Buy Rating at HC Wainwright
HC Wainwright reaffirmed its "buy" rating on Immunovant (NASDAQ:IMVT) with a $35.00 price objective, suggesting a potential upside of 27.32%. Other analysts have also adjusted their ratings and price targets for the biopharmaceutical company, resulting in a consensus "Moderate Buy" rating and a price target of $31.11. Insider selling and institutional investor activity have also been noted, with the stock currently trading at $27.49.
Immunovant stock hits all-time high at 27.87 USD By Investing.com
Immunovant Inc. (IMVT) stock reached an all-time high of $27.87, representing a 32.53% increase over the past year and a 74.97% surge in the last six months. This growth is attributed to advancements in its drug development pipeline and positive market sentiment, with liquid assets exceeding short-term obligations. Analysts maintain a "Strong Buy" rating with a high price target of $57, and the company recently surpassed Q3 2026 EPS expectations.
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
Immunovant, Inc. (IMVT) reported a narrower-than-expected third-quarter fiscal 2026 net loss of 61 cents per share, exceeding the Zacks Consensus Estimate of 72 cents. The company, which currently has no approved products, saw increased research and development expenses due to clinical studies for IMVT-1402, its lead asset. Immunovant aims to advance IMVT-1402 through multiple registrational trials for various autoimmune indications, with key data readouts anticipated in 2026 and 2027.
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
Immunovant, Inc. (IMVT) reported a narrower-than-expected Q3 fiscal 2026 net loss of 61 cents per share, outperforming the Zacks Consensus Estimate of 72 cents. The company, which currently has no approved products, saw increased R&D expenses due to clinical studies for IMVT-1402 but decreased G&A expenses. Immunovant's shares have surged, and it maintains a Zacks Rank #2 (Buy), with key pipeline updates for IMVT-1402 and batoclimab anticipated in 2026 and 2027.
Immunovant, Inc. (NASDAQ:IMVT) Q3 2026 Earnings Call Transcript
This is an earnings call transcript for Immunovant, Inc. (NASDAQ:IMVT) for Q3 2026, which also includes discussion about Roivant's financial results. The call highlights positive Phase II results for brepocitinib in cutaneous sarcoidosis, noting its significant efficacy and favorable safety profile, and discusses the pipeline of ongoing trials for other indications like dermatomyositis and PH-ILD. Executives emphasize the company's strong financial position with $4.5 billion in cash and anticipate a catalyst-rich period with multiple potential commercial launches in the coming years.
Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones
Immunovant Inc (IMVT) saw its shares jump 12.4% after reporting third-quarter fiscal year 2026 results that exceeded analyst expectations with a narrower net loss. The clinical-stage biopharmaceutical company also provided positive updates on its late-stage immunology pipeline, including fully enrolled trials for IMVT-1402 in rheumatoid arthritis and anticipated topline data for batoclimab in thyroid eye disease in the first half of 2026. The company's cash reserves were significantly bolstered by a recent $550 million equity financing, providing a runway through the anticipated launch of its Graves’ disease program.
Does Immunovant’s (IMVT) Narrower Quarterly Per‑Share Loss Reframe Its Long‑Term Risk‑Reward Equation?
Immunovant (IMVT) recently reported a narrower quarterly net loss of US$110.64 million and a reduced loss per share of US$0.61, indicating improved capital efficiency despite a widening nine-month net loss. The company, a clinical-stage immunology firm with no revenue, continues to operate with high risk and relies on external funding and clinical progress. While the market did not see the results as a major catalyst shift, the article highlights the ongoing dependence on funding and upcoming trial milestones, noting a potential overvaluation based on a single fair value estimate.
Immunovant shares climb 7% as fiscal Q3 loss comes in better than expected
Immunovant's shares rose 7% after its fiscal Q3 loss per share of $0.34 was better than the analyst estimate of a $0.38 loss. The company reported revenue of $0.34 million, slightly below the estimated $0.37 million.
Earnings call transcript: Immunovant beats Q3 2026 EPS expectations, stock surges
Immunovant Inc. (IMVT) reported a significant beat on its Q3 2026 EPS, coming in at -0.61 against an expected -0.72, leading to an 8.35% premarket stock surge. The company highlighted a strong cash position of $4.5 billion, promising Phase 2 results for Brepocitinib in cutaneous sarcoidosis, and expressed optimism for future commercial launches and pivotal study readouts in 2026 and beyond. Executives emphasized the drug's strong performance in treating orphan inflammatory diseases with high unmet needs.
Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
Immunovant released its third-quarter financial results for 2025, highlighting significant progress in its clinical trials for IMVT-1402, particularly in difficult-to-treat rheumatoid arthritis, Graves’ disease, and myasthenia gravis, with key data readouts anticipated in 2026 and 2027. The company also announced a successful $550 million financing, extending its cash runway to support the potential commercial launch of IMVT-1402 for Graves’ disease. Despite increased R&D expenses, Immunovant reported a slight decrease in net loss compared to the previous year.
Immunovant (Nasdaq: IMVT) posts Q3 loss but boosts cash with $550M raise
Immunovant (Nasdaq: IMVT) reported a fiscal third-quarter 2025 net loss of $110.6 million, or $0.61 per share, primarily due to high research and development expenses for its autoimmune pipeline. The company boosted its cash position to $994.5 million with a $550 million financing, extending its cash runway through the potential launch of IMVT-1402 in Graves' disease. Key clinical milestones include anticipated topline data for batoclimab in thyroid eye disease in H1 2026 and IMVT-1402 data in rheumatoid arthritis and cutaneous lupus in H2 2026.
Immunovant’s Upcoming Report to Spotlight Clinical Pipeline Progress
Immunovant Inc. is preparing to release its Q3 financial results and a business update this Friday, with investor focus primarily on the company's clinical development timeline. Following a $550 million capital raise in December 2025, Immunovant has secured liquidity through 2027 to advance its lead candidate, IMVT-1402, and progress clinical trials for multiple disease indications. The report will also provide updates on batoclimab study data, anticipated in the first half of 2026, which is crucial for validating its mechanism of action and influencing the broader IMVT-1402 program.
Immunovant’s Upcoming Report to Spotlight Clinical Pipeline Progress
Immunovant Inc. is set to release its third-quarter financial results and a business update this Friday, which will focus on the company's clinical development timeline. Following a successful $550 million capital raise in December 2025, the company has secured liquidity through 2027 and plans to advance its lead candidate, IMVT-1402, through various clinical trials. Investors are also awaiting crucial data from an advanced study of batoclimab in thyroid eye disease, expected in the first half of 2026.
Immunovant, Inc. (IMVT) Stock Analysis: A Biotech Gem With 54.57% Potential Upside
Immunovant, Inc. (IMVT), a clinical-stage biotech company developing treatments for autoimmune diseases, is presented as a high-growth investment opportunity with a potential upside of 54.57%. Despite currently generating no revenue and having a negative free cash flow, the company is supported by strong analyst confidence and favorable technical indicators. Its focus on innovative antibody candidates like IMVT-1402 and batoclimab, combined with its $5.25 billion market cap, positions it as a notable player in the healthcare sector for investors willing to undertake the risks associated with biotech.
Trading the Move, Not the Narrative: (IMVT) Edition
This article analyzes Immunovant Inc. (NASDAQ: IMVT) using AI models to suggest trading strategies. It highlights a weak near-term sentiment but strong long-term outlook, with an exceptional risk-reward short setup. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are outlined for different risk profiles.
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know
Wall Street analysts predict a potential 55.04% upside for Immunovant (IMVT) with a mean price target of $40.31, despite a wide standard deviation in estimates. The article notes that while price targets can be misleading, a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) for IMVT suggest a legitimate reason for optimism regarding the stock's near-term performance. Investors are cautioned to treat price targets with skepticism and consider other factors like earnings revisions.
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know
Wall Street analysts predict a potential 55.04% upside for Immunovant (IMVT), with a mean price target of $40.31. Despite the variability in individual analyst estimates, a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) suggest an optimistic outlook for the stock's near-term performance. However, investors are cautioned against relying solely on price targets, which can often be overly optimistic due to business incentives.
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know
Wall Street analysts are predicting a 55.04% upside potential for Immunovant (IMVT), with a mean price target of $40.31. While price targets alone can be misleading, the increasing optimism reflected in positive earnings estimate revisions and a Zacks Rank #2 (Buy) further support a potential upside for the stock. Investors are advised to use price targets as a starting point for further research rather than the sole basis for investment decisions.
Wall Street Analysts Predict a 55.04% Upside in Immunovant (IMVT): Here's What You Should Know
Wall Street analysts predict a potential 55.04% upside for Immunovant (IMVT) with a mean price target of $40.31, despite the stock gaining only 0.4% in the past four weeks. While individual price targets can be misleading due to potential analyst optimism, a strong agreement in upward earnings estimate revisions and a Zacks Rank #2 (Buy) suggest a legitimate reason for potential stock upside. Investors are advised to use price targets as a starting point for further research rather than the sole basis for investment decisions.
Immunovant (IMVT) Expected to Post Quarterly Earnings on Friday
Immunovant (NASDAQ:IMVT) is scheduled to announce its Q3 2026 earnings before the market opens on Friday, February 6th, with analysts expecting to report ($0.71) EPS. The company missed the previous quarter's consensus estimates and analysts forecast a loss of ($3) EPS for both the current and next fiscal years. The stock is currently trading near its 52-week high, with significant institutional ownership but notable insider selling activity totaling over $1.5 million in the last quarter.
Immunovant, Inc. (IMVT) Stock Analysis: Exploring a 51.55% Upside Potential in the Biotech Sector
Immunovant, Inc. (IMVT) is a biotechnology company focused on developing monoclonal antibody therapies for autoimmune diseases. Analysts project a potential upside of 51.55%, with an average target price of $40.31 against its current stock price of $26.6, supported by positive technical indicators. Despite strong analyst sentiment, the company faces financial challenges, including negative EPS and ROE, highlighting the speculative nature of investing in clinical-stage biotech firms.
Investors Purchase High Volume of Call Options on Immunovant (NASDAQ:IMVT)
Investors purchased a high volume of call options on Immunovant (IMVT), with 2,610 call options traded on Monday, representing a 196% increase over the average volume. The stock has a consensus "Moderate Buy" rating from analysts with an average target price of $30.78, despite some recent insider selling. Immunovant, a clinical-stage biopharmaceutical company, focuses on developing treatments for severe autoimmune diseases by targeting the neonatal Fc receptor.
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Immunovant (Nasdaq: IMVT) will announce its financial results for the third quarter, which ended December 31, 2025, and provide a business update on Friday, February 6, 2026, at 8:00 a.m. ET. A conference call hosted by Roivant (Nasdaq: ROIV) will be available for registration, and webcast details will be posted on Immunovant's investor relations website. Immunovant is a clinical-stage immunology company focused on developing therapies for autoimmune diseases.
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Immunovant (Nasdaq: IMVT) announced it will report its financial results for the third quarter ended December 31, 2025, and provide a business update on Friday, February 6, 2026, at 8:00 a.m. ET. Investors can register online for the conference call and access webcast details on the company's website. Immunovant is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases.
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
Immunovant (Nasdaq: IMVT) announced it will report its financial results for the third quarter ended December 31, 2025, and provide a business update on Friday, February 6, 2026, at 8:00 a.m. ET. Investors can register online for the conference call or access the presentation and webcast details on the company's website. Immunovant is a clinical-stage immunology company focused on developing targeted therapies for people with autoimmune diseases.
Immunovant (NASDAQ:IMVT) CTO Jay Stout Sells 1,977 Shares
Immunovant CTO Jay Stout recently sold 1,977 shares on January 21st at an average price of $26.03, reducing his position by 0.99%. The company, trading around $26 with a $4.56 billion market cap, missed recent EPS estimates, reporting -$0.73 versus a consensus of -$0.72. Analysts currently give Immunovant a "Moderate Buy" rating with a target price of $30.78.
(IMVT) Volatility Zones as Tactical Triggers
The article provides an AI-generated analysis for Immunovant Inc. (NASDAQ: IMVT), highlighting weak near-term sentiment but long-term strength. It outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry/target/stop-loss zones and offers multi-timeframe signal analysis to guide investors.
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Rating of "Moderate Buy" from Brokerages
Immunovant, Inc. (NASDAQ:IMVT) has received an average "Moderate Buy" rating from brokerages, with several analysts offering mixed views including upgrades and price target adjustments. The company's stock is trading near $26.18, and it recently reported a quarterly EPS loss that missed consensus estimates. Insider selling and institutional investment activity have also been noted, with hedge funds increasing their stakes.
SG Americas Securities LLC Has $1.01 Million Stock Holdings in Immunovant, Inc. $IMVT
SG Americas Securities LLC significantly increased its stake in Immunovant, Inc. by 679.7% in Q3, now holding 62,598 shares valued at $1.01 million. Despite this institutional buying, insiders have been net sellers of IMVT stock. Analysts generally have a "Moderate Buy" rating for Immunovant with an average price target of $30.78.
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39%
Wall Street analysts project a 47.39% upside for Immunovant (IMVT), with a mean price target of $40.31. Despite the stock gaining 1.4% recently, the article highlights that a positive trend in earnings estimate revisions and a Zacks Rank #2 (Buy) status indicate potential for further upside, cautioning investors to treat price targets with skepticism but acknowledging their interpretive value.
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39%
Wall Street analysts project a 47.39% upside for Immunovant (IMVT), with a mean price target of $40.31. Despite the variable nature of price targets, strong agreement among analysts on higher earnings estimates and a Zacks Rank #2 (Buy) suggest a solid upside potential for the stock. Investors are advised to treat price targets with skepticism but consider the positive earnings estimate revisions as a good indicator.
How Much Upside is Left in Immunovant (IMVT)? Wall Street Analysts Think 47.39%
Immunovant (IMVT) has a consensus price target of $40.31, suggesting a potential upside of 47.4% according to Wall Street analysts. Despite the general unreliability of price targets, strong agreement among analysts on upward earnings estimate revisions for IMVT indicates a potential short-term upside. The stock currently holds a Zacks Rank #2 (Buy), further supporting its positive outlook.
Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling
Truist has raised its price target for Immunovant (IMVT) to $22, up from $16, while maintaining a Hold rating. This adjustment is based on an updated 2026 financial model, though the core fundamental outlook remains unchanged since 2025. This follows other analyst actions, including Wolfe Research upgrading Immunovant to Outperform with a $50 price target, and Guggenheim maintaining a Buy rating but lowering its price target to $41 due to a recent equity offering.
Price-Driven Insight from (IMVT) for Rule-Based Strategy
This article provides a price-driven insight for Immunovant Inc. (IMVT) for rule-based strategies, noting strong near-term sentiment but a neutral mid- and long-term outlook with elevated downside risk. It details three AI-generated institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, along with multi-timeframe signal analysis. The report highlights key support and resistance levels and current price positioning.
Immunovant stock hits 52-week high at $27.71 By Investing.com
Immunovant Inc. recently hit a new 52-week high of $27.71, more than double its 52-week low, reflecting strong investor confidence and positive market sentiment. The biotechnology company, with a market cap of $5.58 billion, has seen its stock price increase by 15.33% over the past year and 52.17% in the last six months. Analysts have a consensus "Strong Buy" rating, with price targets ranging from $16 to $57, amidst the company's focus on autoimmune disease treatments and recent successful stock offerings.
Immunovant (NASDAQ:IMVT) CTO Jay Stout Sells 1,203 Shares
Immunovant's CTO, Jay Stout, sold 1,203 shares of the company's stock on January 7th for over $31,900, decreasing his ownership by 0.60%. The company's shares traded down by 1.1% following the sale. Immunovant has a "Moderate Buy" consensus from analysts, with a target price of $30.78, despite missing recent EPS expectations.
Immunovant CTO Stout sells $32k in IMVT stock
Immunovant's CTO, Jay S. Stout, recently sold 1,203 shares of IMVT stock for approximately $31,914 to cover tax obligations on vested restricted stock units. These transactions occurred while the stock was trading near its 52-week high, having gained almost 49% in the past six months. Despite an InvestingPro analysis suggesting the stock is slightly overvalued, Immunovant maintains a strong cash position and is debt-free, with positive analyst sentiment regarding its Graves' Disease treatment.
Immunovant stock hits 52-week high at $27.71
Immunovant Inc. (IMVT) stock reached a new 52-week high of $27.71, more than doubling its 52-week low, reflecting strong investor confidence with a 15.33% increase over the past year and a 52.17% surge in six months. Analysts recommend a "Strong Buy," highlighting the company's robust financial flexibility and ongoing development of autoimmune disease treatments. Recent developments include a significant stock offering and upgrades from Wolfe Research and Oppenheimer, despite a reported net loss in Q2 2026, due to a strong cash position and promising pipeline.
Immunovant stock hits 52-week high at $27.71 By Investing.com
Immunovant Inc. stock reached a new 52-week high of $27.71, more than double its 52-week low. The biotechnology company has experienced significant stock price increases over the past year and six months, reflecting strong investor confidence. Analysts have set price targets ranging from $16 to $57, with a consensus toward a "Strong Buy" recommendation.
Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential
Wolfe Research upgraded Immunovant (NASDAQ:IMVT) from Peerperform to Outperform with a $50 price target, citing improved investor perception of the company's Graves’ disease treatment potential and strong financial stability. The upgrade is supported by declining short interest and anticipates positive catalysts in 2026, including data releases for Thyroid Eye Disease and cutaneous lupus. Long-term investors could see a fair value between $64-95 per share.
Wolfe Research upgrades Immunovant stock to Outperform on Graves’ disease potential
Wolfe Research has upgraded Immunovant (NASDAQ:IMVT) from Peerperform to Outperform, setting a price target of $50.00, citing increased investor appreciation for the company's Graves’ disease treatment potential. The upgrade is driven by competitor argenx's entry into the market, establishing a higher valuation floor for Immunovant, and declining short interest. Key upcoming catalysts include Thyroid Eye Disease (TED) data early in 2026 and cutaneous lupus (CLE) results in the second half of the same year.
Wolfe Research Upgrades Immunovant (IMVT)
Wolfe Research upgraded their outlook for Immunovant (IMVT) from Peer Perform to Outperform on January 6, 2026. This upgrade projects a 58.14% upside, with an average one-year price target of $39.49/share based on analyst forecasts. The article also details institutional ownership data, highlighting key holders like Deep Track Capital and Armistice Capital.
(IMVT) Price Dynamics and Execution-Aware Positioning
This article analyzes Immunovant Inc. (NASDAQ: IMVT) price dynamics, indicating conflicting sentiment and elevated downside risk, with no clear long-term support signals. It provides three institutional trading strategies tailored for different risk profiles and holding periods, alongside a multi-timeframe signal analysis outlining near-term, mid-term, and long-term support and resistance levels.
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of "Moderate Buy" from Brokerages
Immunovant, Inc. (NASDAQ:IMVT) has received a consensus "Moderate Buy" rating from eleven brokerages, with an average 1-year price target of $27.63. While insiders have recently sold shares, institutions and hedge funds have increased their positions in the clinical-stage biopharmaceutical company, which is developing the FcRn inhibitor efgartigimod. The company reported a quarterly EPS of -$0.73, slightly missing estimates, and has a market capitalization of $4.59 billion.
